Zach Hopkins, MD
zachhopkinsmd.bsky.social
Zach Hopkins, MD
@zachhopkinsmd.bsky.social
Dermatologist at the University of Utah specializing in autoimmune skin disease (especially bullous and lichen planus conditions). Physician scientist with interests in dermatoepidemiology, patient-reported outcomes, and quality-of-life.
Reposted by Zach Hopkins, MD
David Geier has apparently been commissioned by HHS secretary RFK, Jr. to study potential links between vaccination and autism.

He and his father have 2 papers in 2017/2016 claiming to show Hep-B vaccination greatly increases risk of autism/obesity.

However, their studies have FATAL FLAW...
March 26, 2025 at 2:20 PM
Reposted by Zach Hopkins, MD
The general vibe we are getting across #NIH institutes is deeply bleak — that the agency is nearly, if not already dead.

Top people are leaving or have left. Nearly everyone's looking for other jobs. People still care about what NIH was, but are growing resigned to its death.

1/
March 20, 2025 at 2:42 AM
Reposted by Zach Hopkins, MD
The administration is working on demolishing AHRQ, the agency whose mission is to improve healthcare quality and safety.

www.offmessage.net/p/the-trump-...
The Trump Administration Goes To War With Health-Care Quality
Inside its plan to destroy a small agency that keeps you safe.
www.offmessage.net
March 19, 2025 at 7:06 PM
Reposted by Zach Hopkins, MD
A 2-year-old boy presented with a 1-week history of itchy, red spots. Tense vesicles, erosions, and inflammatory plaques were seen. Direct immunofluorescence revealed a linear band of IgA at the dermoepidermal junction. Read the full case details: nej.md/3R6CIIA

#MedSky #DermSky #PedSky
March 16, 2025 at 1:36 PM
Reposted by Zach Hopkins, MD
When the data on which we make guidelines and recommendations comes almost exclusively from one ancestry group (in this case, white folks of European ancestry), the recommendations will be less effective for those from other backgrounds. That’s part of why health equity matters.
March 19, 2025 at 3:43 PM
Reposted by Zach Hopkins, MD
Doing a test run for my NIH grant pilot trial today: I donated a bit of blood and the research coordinators are finalizing the blood processing workflow

This is a study of vitamin supplementation for knee osteoarthritis
March 19, 2025 at 5:39 PM
Reposted by Zach Hopkins, MD
I received this reply from @davemccormick.bsky.social re: #NIH indirects. I am still waiting to hear from @fetterman.senate.gov. #NIH funding is a key economic driver and is responsible for the cures & miracles I see in my clinic every day. Contact your reps at @5calls.org
#DermSky #SciSky #MedSky
March 18, 2025 at 1:23 AM
Excited to announce that my @dermatologyfoundation public health career development proposal was accepted "Development of a patient-reported outcome-based autoimmune skin disease monitoring program." This proposal centers on innovative applications of patient-reported outcomes for disease monitoring
March 17, 2025 at 5:36 PM
Reposted by Zach Hopkins, MD
Rituximab shows long-term efficacy in Pemphigus Foliaceus & Vulgaris patients. Exciting data from a cohort study! #Dermatology PMID:40042819, JAMA Dermatol 2025 https://doi.org/10.1001/jamadermatol.2024.6654 #Medsky 🧪
https://doi.org/10.1001/jamadermatol.2024.6654
No description available
doi.org
March 10, 2025 at 6:40 AM
Reposted by Zach Hopkins, MD
Some more evidence from a meta-analysis of 6 RCTs to support that subdermal implants (i.e. Nexplanon) are more likely to cause acne than hormonal IUDs (OR 2.21). Something to keep in mind for those concerned about acne who otherwise don't have strong preferences.
pubmed.ncbi.nlm.nih.gov/40069520/
Subdermal implants vs. levonorgestrel intrauterine devices outcomes in reproductive-aged women: a systematic review and meta-analysis - PubMed
PROSPERO ID: CRD42024516472.
pubmed.ncbi.nlm.nih.gov
March 13, 2025 at 1:49 PM
Reposted by Zach Hopkins, MD
For better or for worse (worse), MEASLES are back, so here's a #skytorial on recognizing this once thought eradicated disease.

MEASLES: a tutorial!

#dermsky #medsky #MedEd
1/
March 2, 2025 at 1:13 PM
Reposted by Zach Hopkins, MD
In two trials involving patients with chronic spontaneous urticaria, remibrutinib led to significantly greater reductions than placebo in itching and hives at week 12. Full results of the REMIX-1 and REMIX-2 trials: nej.md/41uQD07

#MedSky #DermSky
March 9, 2025 at 1:36 PM